A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 29 to 34 Weeks PMA: Dose Escalation and Study Extension

Trial Profile

A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 29 to 34 Weeks PMA: Dose Escalation and Study Extension

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Apr 2017

At a glance

  • Drugs Sinapultide (Primary)
  • Indications Neonatal respiratory distress syndrome
  • Focus Adverse reactions
  • Sponsors Discovery Laboratories; Windtree Therapeutics
  • Most Recent Events

    • 28 Nov 2016 Results published in the Windtree Therapeutics Media Release
    • 28 Nov 2016 According to a Windtree Therapeutics media release, data from this trial was presented at the 6th International Congress of European Neonatal and Perinatal Societies (UENPS)
    • 28 Apr 2016 According to a Windtree Therapeutics media release, data from this study will be presented as a poster at the 2016 Pediatric Academic Societies (PAS) Meeting 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top